Table 1 Demographic, anthropometric, and clinical variables of the total study cohort and those stratified by screening results for anxiety and depression, unadjusted data

Sociodemographic / anthropometric data

Age, years, mean (SD)

Female gender, no. (%)

BMI-SDS, mean (SD)

Underweight, no. (%)

Normal weight, no. (%)

Overweight / obesity, no. (%)

15.6 (2.2)

790 (68.8)

-0.02 (1.2)

136 (12.6)

722 (66.9)

222 (20.6)

15.8 (2.1)

255 (81.0)

0.08 (1.1)

26 (8.5)

203 (66.6)

76 (24.9)

15.2 (2.3)

415 (63.7)

-0.11 (1.2)

85 (14.2)

411 (68.6)

103 (17.2)

< 0.0001

< 0.0001

0.028

0.014

0.531

0.006

Type of school, no. (%)

 Lowest/middle German secondary school

 Highest German secondary school

382 (48.5)

405 (51.5)

98 (48.5)

104 (51.5)

224 (48.7)

236 (51.3)

0.966

0.966

JIA specific data

Disease duration, years, mean (SD)

Age at disease onset, years, mean (SD)

7.2 (4.9)

8.4 (4.9)

7.3 (5.1)

8.5 (5.0)

7.2 (4.8)

8.0 (4.7)

0.962

0.180

JIA category, no. (%)

 RF-positive polyarthritis

 RF-negative polyarthritis

 Systemic JIA

 Persistent oligoarthritis

 Extended oligoarthritis

 Psoriatic arthritis

 Enthesitis-related arthritis

 Unclassified JIA

48 (4.2)

252 (21.9)

38 (3.3)

325 (28.5)

171 (14.9)

87 (7.6)

174 (15.1)

41 (3.6)

17 (5.4)

82 (25.9)

10 (3.2)

70 (22.2)

54 (17.1)

27 (8.5)

47 (14.9)

7 (2.2)

22 (3.4)

141 (21.7)

21 (3,2)

191 (29.3)

99 (15.2)

50 (7.7)

93 (14.3)

29 (4.5)

0.139

0.140

0.957

0.017

0.457

0.646

0.814

0.084

cJADAS-10, (0–30), mean (SD)

PGA score, NRS 0–10, mean (SD)

Inactive disease*, no. (%)

No. of joints with active disease, mean (SD)

4.6 (4.7)

1.4 (2.0)

480 (53.6)

0.9 (2.5)

6.1 (5.1)

1.7 (2.1)

114 (46.9)

1.1 (2.8)

3.8 (4.3)

1.2 (1.8)

294 (57.8)

0.8 (2.5)

< 0.0001

< 0.0001

0.005

0.096

Laboratory parameters, median (Interquartile Range)

C-reactive protein, mg/l

Erythrocyte sedimentation rate, mm/h

0.8 (3.2)

7.0 (10.0)

0.9 (3.7)

7.0 (11.3)

0.6 (2.5)

6.0 (8.0)

0.022

0.007

Drug therapy (past 12 months)

Low-dose GCs (< 0.2 mg/kg/day), no. (%)

High-dose GCs (≥ 0.2 mg/kg/day), no. (%)

Any conventional synthetic DMARD, no. (%)

Any biologic DMARD, no. (%)

72 (6.8)

38 (3.6)

458 (40.9)

433 (38.5)

26 (8.8)

16 (5.5)

137 (44.8)

128 (41.0)

30 (5.0)

14 (2.4)

248 (39.0)

240 (37.7)

0.028

0.016

0.091

0.320

Patient-reported data

C-HAQ total score (0–3), mean (SD)

Well-being, NRS 0–10, mean (SD)

Pain intensity, NRS 0–10, mean (SD)

Fatigue, NRS 0–10, mean (SD)

Coping, NRS 0–10, mean (SD)

Hospital days (past 12 month), mean (SD)

0.24 (0.5)

2.5 (2.5)

2.4 (2.7)

2.2 (2.9)

1.7 (2.3)

2.1 (8.5)

0.44 (0.6)

3.5 (2.6)

3.5 (2.9)

4.1 (3.3)

2.8 (2.6)

2.4 (6.5)

0.14 (0.3)

1.8 (2.1)

1.9 (2.5)

1.2 (2.1)

1.1 (1.8)

1.7 (6.0)

< 0.0001

< 0.0001

< 0.0001

< 0.0001

< 0.0001

0.073

Modifiable lifestyle factors

Physical fitness^€, no. (%)

Regular sports participation, no. (%)

Sufficient physical activity^¥, no. (%)

554 (62.1)

599 (63.9)

192 (18.3)

120 (46.5)

154 (54.4)

47 (16.6)

398 (70.1)

401 (68.1)

112 (18.9)

< 0.0001

< 0.0001

0.407